[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-deficiency-anemia-ida\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-deficiency-anemia-ida":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,77,108,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100635749","phase-3-comparison-of-ferrous-salt-vs-liposomal-iron-in-adult-women-with-iron-deficiency-anemia-100635749",false,"NCT07556731","Comparison of Ferrous Salt vs. Liposomal Iron in Adult Women With Iron-Deficiency Anemia","IDA","Inclusion Criteria:\n\n* Female patients of reproductive age (15 to 49 years) with a diagnosis of iron-deficiency anemia secondary to dysfunctional uterine bleeding.\n* Patients with iron-deficiency anemia who are treatment-naïve or whose last administration of iron therapy, either oral or parenteral, occurred at least three months prior to enrollment and who continue to have anemia.\n* Patients with a functional oral route.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with abnormal uterine bleeding secondary to cancer\n* Severe intolerance to iron supplementation\n* Patients with gastritis or chronic use of proton pump inhibitors\n* Concomitant treatment with dietary supplements rich in calcium, magnesium, or zinc\n* Patients with endocrine disorders (hypothyroidism, hyperthyroidism)\n* Uncontrolled type 2 diabetes mellitus\n* Associated gastrointestinal bleeding\n* Patients with esophageal disorders","FEMALE","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this study is to compare ferrous salt and liposomal iron for the treatment of iron-deficiency anemia in adult women. The study will also evaluate how well each treatment is tolerated.\n\nThe main questions this study aims to answer are:\n\nDoes liposomal iron increase hemoglobin levels as effectively as ferrous salt?\n\nAre there differences in side effects, especially gastrointestinal symptoms, between the treatments?\n\nDoes dosing ferrous salt every other day improve tolerance compared to daily dosing?\n\nResearchers will compare three oral iron treatment strategies to determine which approach provides the best balance between effectiveness and tolerability.\n\nParticipants will:\n\nBe adult women diagnosed with iron-deficiency anemia\n\nBe randomly assigned to one of three groups:\n\nDaily ferrous salt Ferrous salt taken every other day Daily liposomal iron Take the assigned iron treatment for 3 months Have blood tests at the beginning and end of the study to measure hemoglobin and iron levels Report any side effects or intolerance during treatment",[26,27,28,29],"Iron-deficiency Anemia (IDA)","Hemoglobin","Iron Deficiencies","Adverse Effect",[31,32,33,34,35],"Iron-deficiency anemia treatment comparision","Oral iron dosing","Liposomal iron","Iron replacement therapy","ferritin","NOT_YET_RECRUITING","2026-04-22",{"date":39,"type":40},"2026-04-29","ACTUAL",{"date":42,"type":20},"2026-05-01",{"date":44,"type":20},"2027-07-01",{"name":46,"class":47},"Hospital General de Mexico","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100553932","phase-4-oral-iron-supplementation-on-alternate-vs-consecutive-days-for-iron-deficiency-anemia-in-pregnancy-100553932","NCT06492512","Oral Iron Supplementation on Alternate vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy","Inclusion Criteria:\n\n* Pregnant patients will be enrolled at less than 30 weeks gestational age (GA) with laboratory confirmed IDA (as defined by hemoglobin under 10.5 g\u002FdL, as well as ferritin under 15 mcg\u002FL)\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old, patients who have severe IDA that requires blood transfusion or IV iron infusion, patients who have other known hemoglobinopathy (such as thalassemia or sickle cell anemia) or anemia of different mechanism (such as vitamin B12 or folate deficiency), patients with ulcerative colitis, Crohn's disease, gastric ulcers, patients who have previously undergone gastric bypass surgery, patients who experience admission for antepartum bleed, have been diagnosed with abnormal placentation (i.e., placenta previa, placenta accreta, placenta increta or percreta)","45 Years",{"count":57,"type":20},120,[59],"PHASE4","This will be a randomized clinical trial. Enrolled subjects will be randomized (1:1) into two study arms to receive either daily (Group 1) or alternate day (Group 2) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill.",[26,62],"Pregnancy",[64,65],"Iron-deficiency anemia (IDA)","Iron-deficiency anemia (IDA) during gestation","RECRUITING","2026-04-21",{"date":69,"type":40},"2026-04-24",{"date":71,"type":40},"2025-05-27",{"date":73,"type":20},"2029-07-30",{"name":75,"class":76},"Southern Illinois University","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100616681","phase-4-efficacy-and-tolerability-of-sucrosomial-iron-vs-ferric-maltol-in-iron-deficient-women-100616681","NCT07308769","Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women","A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women","SID-WOMEN","Inclusion Criteria:\n\n* Female participants ≥ 18 years\n* Mild anemia (11.0 ≤ Hb \\\u003C 12 g\u002FdL) or moderate anemia (8.0 \\\u003C Hb \\\u003C 11 g\u002FdL)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of iron-containing drugs or supplements within 1 month prior to screening\n* Psychiatric disorders interfering with consent or compliance\n* Active cancer (except fibroids and polyps)\n* Pregnant or breastfeeding women\n* Participation in another interventional study\n* History of poor adherence or inability to comply\n* Use of erythropoietin within 3 months prior to screening\n* Need for blood transfusion or IV iron (per investigator judgment)\n* Severe active IBD (HBI \\> 16 for Crohn; CAI \\> 12 for ulcerative colitis)\n* Previous bariatric surgery\n* Alcohol abuse\n* Hemochromatosis or iron overload syndromes\n* Hereditary anemias (including thalassemia)\n* Known hypersensitivity to study product ingredients",{"count":86,"type":20},146,[59],"This study aims to compare two oral iron treatments, Sucrosomial® Iron and Ferric Maltol, in women with mild to moderate iron deficiency anemia. Many patients experience gastrointestinal side effects or poor tolerability with traditional iron supplements, which may limit adherence. Participants will be randomly assigned to receive either Sucrosomial® Iron or Ferric Maltol for 12 weeks. The primary objective is to determine whether Sucrosomial® Iron is as effective as Ferric Maltol in normalizing hemoglobin levels.",[90,91],"Anemia","Iron Deficiency Anemia (IDA)",[93,94,95,96],"Iron Deficiency","Iron Deficiency Anemia","Mild to Moderate Anemia","anemia in women","2026-03-20",{"date":99,"type":40},"2026-03-23",{"date":101,"type":40},"2025-12-11",{"date":103,"type":20},"2026-10",{"name":105,"class":106},"Pharmanutra S.p.a.","INDUSTRY",7,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":116,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":48},"100597052","phase-4-ironica-iron-repletion-in-heart-failure---a-comparison-of-oral-and-iv-approaches-100597052","NCT07053475","IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches","IRONICA: IRON Repletion in Congestive Heart Failure - A Randomized Controlled Trial Comparing Oral Versus IV Approaches","IRONICA","Inclusion Criteria:\n\n* Age ≥18 years\n* BMI ≥18.0 kg\u002Fm²\n* Hemoglobin:\n\n\\> 9 g\u002FdL and \\\u003C14 g\u002FdL for men \\> 9 g\u002FdL and \\\u003C13 g\u002FdL for women\n\n* Diagnosed with Congestive Heart failure:\n\nHFrEF: EF ≤40% in any recent echocardiogram HFpEF: EF ≥50-55% without any prior EF ≤40%, and evidence of diastolic dysfunction per ASE\u002FEACVI 2023 criteria-defined as either grade ≥2 or ≥2 supporting echo parameters (septal e' \\\u003C7 cm\u002Fsec or lateral e' \\\u003C10 cm\u002Fsec, E\u002Fe' ≥15, TR velocity \\>2.8 m\u002Fs, LA volume index ≥34 mL\u002Fm², LV septal or posterior wall thickness ≥1.2 cm, or LA area ≥20 cm² \u002F diameter ≥3.8 cm.\n\n* Documented elevated NT-proBNP based on BMI and rhythm:\n\nBMI \\\u003C35: ≥220 pg\u002FmL (NSR) or ≥660 pg\u002FmL (A-Fib) BMI ≥35: ≥125 pg\u002FmL (NSR) or ≥375 pg\u002FmL (A-Fib)\n\n* NYHA Class II-IV\n* Transferrin saturation (TSAT) \\\u003C20%\n* Hemoglobin \\\u003C14 g\u002FdL for men, \\\u003C 13 g\u002FdL for women.\n* Stable on heart failure therapy for ≥2-4 weeks\n* Currently prescribed a diuretic at home\n* Ambulatory (able to walk \\>20 ft with minimal assistance)\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Received IV iron, ESA, or blood transfusion within the last 6-12 months\n* Received high-dose oral iron (\\>100 mg\u002Fday in past 7 days)\n* Severe renal impairment (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m² or on dialysis)\n* Patients with known cirrhosis or transaminitis with AST \\>141 or ALT \\>112 IU\u002FL\n* Active bleeding or known bleeding disorder\n* Recent cardiac surgery, myocardial infarction, or stroke within past 3 months\n* Active infection, defined as any systemic or deep-seated infection (e.g., bacteremia, sepsis, osteomyelitis, or infections requiring IV antibiotics or hospitalization) at the time of screening.\n* Active malignancy or undergoing chemotherapy\u002Fradiotherapy\n* Vitamin B12 or folate deficiency (unless corrected prior to enrollment)\n* Chronic liver disease (with LFTs \\>3× upper limit of normal)\n* Pregnant or breastfeeding women or those not using effective contraception\n* Lacks capacity to consent or unable to comply with study procedures","ALL","100 Years",{"count":119,"type":20},250,[59],"The goal of this clinical trial is to learn which iron treatment works better for adults with congestive heart failure and low iron levels: intravenous (IV) iron given through a vein or oral (PO) iron taken by mouth. Participants must have heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) and a transferrin-saturation (TSAT) level below 20 percent.\n\nThe main questions the study will answer are:\n\n1. Does IV iron raise walking distance on a 6-minute walk test more than oral iron after 24 weeks?\n2. Does IV iron improve symptoms and quality of life more than oral iron?\n3. How do the two treatments compare for safety, side effects, and hospital readmissions\u002F mortality?\n\nResearchers will compare IV ferric carboxymaltose with oral ferrous sulfate to see which option helps people feel and function better.\n\nWhat participants will do\n\n* Be randomly assigned by (like flipping a coin) to IV iron or oral iron.\n* Receive either a one-time IV iron infusion (with possible repeat at 12 weeks) or take iron pills twice each day for 24 weeks.\n* Visit the infusion clinic at 6 weeks for second dose of IV iron if needed.\n* Visit the clinic at 12 weeks for a follow-up to gather follow-up data including\n\n  1. A 6-minute walk test\n  2. Brief symptom and quality-of-life surveys\n  3. Blood tests to measure serum iron, ferritin, and transferrin saturation\n\nThis study will help doctors decide whether IV or oral iron is the safer, more effective way to treat iron deficiency in people with heart failure in our local community.",[123,124,125,93,26],"Heart Failure","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)",[127,128,129,130,131,132,133,134,135,136,137,138,139],"Intravenous iron","Oral iron","Ferric carboxymaltose","Ferrous sulfate","Transferrin saturation (TSAT)","Functional iron deficiency","6-minute walk test (6MWT)","Kansas City Cardiomyopathy Questionnaire (KCCQ)","Quality of life","Randomized controlled trial","Congestive heart failure","HFpEF","HFrEF","2025-06-26",{"date":142,"type":40},"2025-07-08",{"date":144,"type":40},"2025-04-02",{"date":146,"type":20},"2027-03-31",{"name":148,"class":76},"Syed Hamza Mufarrih",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":116,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":48},"100565050","patient-blood-management-in-patients-scheduled-for-cardiac-surgery-100565050","NCT06637137","Patient Blood Management in Patients Scheduled for Cardiac Surgery","Patient Blood Management in Cardiac Surgical Patients: the ICARUS-2 Study","ICARUS-2","Inclusion Criteria:\n\n\\- all adult patients scheduled for elective cardiac surgery\n\nExclusion Criteria:\n\n* pregnancy\n* dyalisis\n* patient's refusal",{"count":158,"type":20},464,"OBSERVATIONAL","The ICARUS 2 study has the general objective of collecting data in patients undergoing cardiac surgery; in our centre, in order to optimize and improve hemoglobin values, a team of haematologists, assisted by cardio anesthetists and cardiac surgeons, will evaluate the blood tests of patients scheduled for elective cardiac surgery in order to correct any states of hypoferritinemia (low iron in the blood) to promote recovery from blood losses related to cardiac surgery. This objective is strongly encouraged by the good use of blood programs currently in force at our foundation.\n\nIn particular, the research presented here intends to demonstrate a reduction in the number of intra- and post-operative transfusions.",[90,162,163,91,164,165],"Anemia, Iron-Deficiency","Iron Deficiency Anemia Treatment","Cardiac Surgical Patients","Blood Loss, Surgical",[167,168,169,170],"iron","anemia","cardiac surgery","patient blood management","2025-02-24",{"date":173,"type":40},"2025-02-26",{"date":171,"type":40},{"date":176,"type":20},"2027-02-28",{"name":178,"class":76},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]